Agnes Ewongwo ¹ Aji Fatou Sahor ² Wilfred Ngwa ³ Chika Nwachukwu ^4*

• ¹ Stanford University, Stanford, United States
• ² University of Texas Health Science Center at Houston, Houston, Texas, United States
• ³ Johns Hopkins Medicine, Johns Hopkins University, Baltimore, Maryland, United States
• ⁴ UC San Diego Health, University of California, San Diego, San Diego, California, United States

A woman dies due to cervical cancer every two minutes. Cervical cancer causes more than 311,000 preventable deaths per year. 85% of these deaths are in low- and middle-income countries. Cervical cancer is caused by the human papillomavirus virus (HPV). However, it is preventable through vaccination and screening. Given the critical role of HPV vaccination to prevent millions of deaths, this review paper aims to understand the barriers to implementing HPV vaccination in developing countries as well as to give innovative solutions to each impediment as evidenced by demonstration projects, pilot studies, and evidence-based research. PubMed, Embase, and Cochrane Database of Systemic Reviews were systematically searched for the terms. Identifiable barriers to a successful vaccine implementation program in a developing country include cost, societal and cultural values, misinformation, logistics of vaccine delivery, and human resources. Solutions to these barriers include a subsidized vaccine cost, community sensitization before vaccine introduction, well-trained media professionals to dispel myths, and partnerships with public and private sectors. This aggregate of data can help inform future developing countries' implementation programs to further the World Health Assembly mission to vaccinate 90% of eligible girls globally by 2030.